Immuno-Biological Laboratories (4570) · InitiativeRestated
Practical Application of Biobetter Antibodies with High ADCC Activity
First written in FY2018-Q2. 1 of 2 entries say "Restated". Latest entry: FY2020.
2entries
4years
0from disclosures
How it moved
Same theme, other companies
Practical application of biobetters based on high-ADCC antibodies derived from genetically modified silkwormsA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2020RestatedAnnual report
「In particular, antibodies can exhibit high ADCC activity because they do not have fucose in their glycans.」
The company continues to pursue the development of pharmaceuticals containing antibodies with high ADCC activity, using the glycan characteristics of genetically modified silkworms. - FY2018-Q2First statedAnnual report
「The company aims to leverage the advantage of genetically modified silkworms, which can produce antibodies with high ADCC activity because of their distinctive glycan structures, to manufacture antibodies for treating cancer and other diseases and commercialize them as biobetters.」
The company has disclosed for the first time a plan to commercialize antibodies with high ADCC activity as biobetters for treating cancer and other diseases, leveraging the glycan characteristics of genetically modified silkworms.